Aperçu rapide pour Recombinant Human IgG1 isotype control (Biotin) (ABIN7488562)
Antigène
IgG1
Type d'anticorp
Recombinant Antibody
Clonalité
Monoclonal
Conjugué
Biotin
Application
Isotype Control (IsoC), ELISA, Western Blotting (WB), Immunohistochemistry (IHC), In vivo Studies (in vivo), Immunofluorescence (IF), In vitro Assay (in vitro), Negative Control (NC)
Classe de qualité
MALS verified
Isotype
IgG1
Hôte
Human
Fonction
Biotinylated Human IgG1 Kappa Isotype Control (Biotin, mAb, carrier free, MALS verified)
Specificité
Specifically reacts with DNP (Dinitrophenyl) and DNP conjugated proteins.
Attributs du produit
Dinitrophenyl (DNP) is a hapten that is not normally expressed in the target tissue. Therefore, anti-DNP antibody has no relevant specificity to a target antigen, and can be used as isotype control antibody to differentiate non-specific background signal from specific antibody signal in various in vitro and in vivo studies. Biotinylated Human IgG1 Kappa Isotype Control (mAb) was purified from HEK293 cell culture. It is the chemically biotin labeled form of Human IgG1 Kappa Isotype Control (mAb) DNP-M2).
This antibody is suitable for use as a non-targeting isotype control in various in vitro and in vivo studies. It can also be used as a negative control in various applications such as ELISA, Western blot, immunofluorescence, immunohistochemistry
Restrictions
For Research Use only
Format
Lyophilized
Stock
-20 °C
Antigène
IgG1
Classe de substances
Antibody
Sujet
A hapten is a small molecule that can elicit an immune response only when conjugated with a large carrier such as a protein. Typical haptens include drugs, urushiol, quinone, steroids, etc. Peptides and non-protein antigens usually need conjugating to a carrier protein (such as BSA (bovine serum albumin) or KLH (keyhole limpet hemocyanin) to become good immunogens). Additionally, haptens should be administered with an adjuvant to ensure a high quality immune response. It is important that the hapten design (preserving greatly the chemical structure and spatial conformation of target compound), selection of the appropriate carrier protein and the conjugation method are key conditions for the desired specificity anti-hapten antibodies. We design anti-hapten antibodies based on the HaptenDB information.